Tamma, Pranita DRodriguez-Bano, Jesus2023-01-252023-01-252017http://hdl.handle.net/10668/11031The continued rise in infections caused by extended-spectrum β-lactamase (ESBL)-producing pathogens is recognized globally as one of the most pressing concerns facing the healthcare community. Carbapenems are widely regarded as the antibiotics of choice for the treatment of ESBL-producing infections, even when in vitro activity to other β-lactams has been demonstrated. However, indiscriminant carbapenem use is not without consequence, and carbapenem overuse has contributed to the emergence of carbapenem-resistant Enterobacteriaceae. The use of non-carbapenem β-lactams for the treatment of ESBL infections has yielded conflicting results. In this review, we discuss the available data for the use of cephamycins, cefepime, piperacillin-tazobactam, ceftolozane-tazobactam, and ceftazidime-avibactam for the treatment of ESBL infections.enESBLscarbapenemscefepimecephamycinspiperacillin-tazobactam.Anti-Bacterial AgentsCefepimeCephalosporinsCephamycinsEnterobacteriaceaeEnterobacteriaceae InfectionsHumansMicrobial Sensitivity TestsPenicillanic AcidPiperacillinPiperacillin, Tazobactam Drug CombinationTreatment Outcomebeta-Lactam Resistancebeta-Lactamase Inhibitorsbeta-Lactamasesresearch article28362938open access10.1093/cid/cix0341537-6591PMC5848369https://academic.oup.com/cid/article-pdf/64/7/972/24254903/cix034.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5848369/pdf